The metformin treatment profiles reflect significant differences in branched chain amino acid catabolism, CYP1A2 activity, phosphatidylcholines and phospholipid metabolism, and lipid desaturase activity that are linked to cancer-promoting pathways. The gene discussed is CYP1A2; the disease is cancer.